| SC 13G/A | 2022-01-28 | Frazier Life Sciences VIII, L.P. | Sierra Oncology, Inc. | 148,148 | 1.0% | EDGAR |
| SC 13D/A | 2021-11-08 | Longitude Capital Partners III, LLC | Sierra Oncology, Inc. | 3,441,896 | 20.2% | EDGAR |
| SC 13D/A | 2021-11-05 | Abingworth LLP | Sierra Oncology, Inc. | 2,043,626 | 12.6% | EDGAR |
| SC 13D/A | 2021-11-05 | ORBIMED ADVISORS LLC | Sierra Oncology, Inc. | 3,044,753 | 18.1% | EDGAR |
| SC 13G/A | 2021-11-05 | Vivo Capital IX, LLC | Sierra Oncology, Inc. | 431,947 | 3.4% | EDGAR |
| SC 13G | 2021-08-16 | Frazier Life Sciences Public Fund, L.P. | Sierra Oncology, Inc. | 148,148 | 1.2% | EDGAR |
| SC 13G | 2021-04-01 | ADAGE CAPITAL PARTNERS GP, L.L.C. | Sierra Oncology, Inc. | 794,140 | 6.8% | EDGAR |
| SC 13G/A | 2021-02-16 | CAXTON CORP | Sierra Oncology, Inc. | 1,142,361 | 9.9% | EDGAR |
| SC 13G/A | 2021-02-16 | Mangrove Partners Master Fund, Ltd. | Sierra Oncology, Inc. | 587,464 | 5.1% | EDGAR |
| SC 13G/A | 2021-02-16 | Mangrove Partners Master Fund, Ltd. | Sierra Oncology, Inc. | 548,869 | 4.8% | EDGAR |
| SC 13G/A | 2021-02-16 | Rock Springs Capital Management LP | Sierra Oncology, Inc. | 567,358 | 5.1% | EDGAR |
| SC 13G | 2020-10-19 | Rock Springs Capital Management LP | Sierra Oncology, Inc. | 555,077 | 5.3% | EDGAR |
| SC 13D/A | 2020-04-29 | Frazier Life Sciences VIII, L.P. | Sierra Oncology, Inc. | 148,148 | 1.4% | EDGAR |
| SC 13G/A | 2020-02-13 | Broadfin Capital, LLC | Sierra Oncology, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2020-02-13 | New Leaf Biopharma Opportunities I, L.P. | Sierra Oncology, Inc. | 125,511 | 1.2% | EDGAR |
| SC 13G/A | 2020-02-13 | Vivo Capital IX, LLC | Sierra Oncology, Inc. | 324,783 | 3.1% | EDGAR |
| SC 13D/A | 2020-02-10 | Longitude Capital Partners III, LLC | Sierra Oncology, Inc. | 1,477,320 | 14.2% | EDGAR |
| SC 13D | 2020-02-10 | Abingworth LLP | Sierra Oncology, Inc. | 2,035,752 | 9.9% | EDGAR |
| SC 13G | 2020-02-10 | GILEAD SCIENCES INC | Sierra Oncology, Inc. | 1,073,300 | 10.0% | EDGAR |
| SC 13G | 2020-02-03 | CAXTON CORP | Sierra Oncology, Inc. | 1,082,200 | 9.9% | EDGAR |